CD19 - A Promising Pan-Cancer Immune Marker
5 Jun 2024 • CD19 is a promising biomarker in predicting tumors and target immunotherapy. Drugs targeting CD19 could potentially kill various tumors.
CD19, a gene differentially expressed in various cancers, prolongs cancer patient survival and is strongly associated with tumor mutation burden (TMB), microsatellite instability (MSI), and tumor microenvironment (TME). It can synergize with immune-related pathways, controlling immune responses and antigen presentation in tumor immunotherapy.
- A study comparing CD19 mRNA and protein expression in tumor and normal samples found that certain cancer types, such as BRCA, diffuse large B-cell lymphoma, glioblastoma multiforme, head and neck squamous carcinoma, kidney renal clear cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, and uterus corpus endometrial cancer, showed higher CD19 expression compared to normal tissues.
- Conversely, CD19 levels were reduced in colon adenocarcinoma, kidney chromophobe, rectum adenocarcinoma, prostate adenocarcinoma, and thyroid carcinoma.
The study suggests that tumor disease progression may be associated with decreased CD19 expression in the advanced stages of many cancers. High CD19 expression is expected to improve the prognosis of tumor patients. Tumors with high CD19 expression are sensitive to various chemotherapeutic drugs and molecules.
Source: Dovepress | Read full story